31/01/2017 - 06:08

Pharmaust banks $400k rebate from Feds after successful anti cancer trials

31/01/2017 - 06:08


Upgrade your subscription to use this feature.

ASX listed PharmAust has received a $400,000 rebate from the Federal Government in recognition of their cutting edge research and development program being undertaken at two of the Perth-based company’s wholly owned subsidiaries.  Pharmaust’s new anti-cancer drug, Monepantel, has been powering though human and K9 trials with considerable success. 

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options